Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck
Robert I. Haddad(Broad Institute), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Bernadette Lake‐Willcutt(Dana-Farber Cancer Institute), Paul M. Busse(Massachusetts General Hospital), Charles M. Norris, A. Dimitrios Colevas(Cancer Institute (WIA)), Roy B. Tishler(Dana-Farber Cancer Institute), Christopher A. Sullivan(Brigham and Women's Hospital), Mary Ann Case(Dana-Farber Cancer Institute), Rosemary Costello(Dana-Farber Cancer Institute), Laura A. Goguen(Brigham and Women's Hospital)
Cited by 91
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926